Bristol-Myers Squibb (BMY) Market Cap (1999 - 2026)
Bristol-Myers Squibb (BMY) market cap from Nov 1, 1999 to Jul 20, 2026. The current Bristol-Myers Squibb (BMY) market cap is $123B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Market Cap
Bristol-Myers Squibb (BMY) Market Cap CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +1.66% |
| 3 Years TTM | -10.39% |
| 5 Years TTM | -5.25% |
| 10 Years TTM | -0.29% |
| All Time TTM | -0.45% |
Annual Market Cap change of Bristol-Myers Squibb (BMY)
| Year | Market Cap | Change |
|---|---|---|
| 2026 | $123B | +11.68% |
| 2025 | $110B | -4.26% |
| 2024 | $115B | +8.68% |
| 2023 | $106B | -31.23% |
| 2022 | $153B | +10.92% |
| 2021 | $138B | -1.18% |
| 2020 | $140B | +33.64% |
| 2019 | $105B | +23.49% |
| 2018 | $85B | -15.54% |
| 2017 | $100B | +2.85% |
| 2016 | $98B | -14.89% |
| 2015 | $115B | +17.24% |
| 2014 | $98B | +11.87% |
| 2013 | $87B | +61.13% |
| 2012 | $54B | -9.26% |
| 2011 | $60B | +31.99% |
| 2010 | $45B | -11.90% |
| 2009 | $51B | +8.60% |
| 2008 | $47B | -12.33% |
| 2007 | $54B | +0.76% |
| 2006 | $54B | +14.53% |
| 2005 | $47B | -10.30% |
| 2004 | $52B | -10.42% |
| 2003 | $58B | +23.54% |
| 2002 | $47B | -54.61% |
| 2001 | $104B | -31.03% |
| 2000 | $151B | +15.19% |
| 1999 | $131B | N/A |
Comparison Bristol-Myers Squibb (BMY) market cap with competitors
Bristol-Myers Squibb (BMY) market cap is $122.65B.
| Ticker | Name | Market Cap | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | $1.03T | +743.24% |
| JNJ | Johnson & Johnson | $594.97B | +385.11% |
| ABBV | Abbvie Inc | $432.22B | +252.41% |
| AZN | Astrazeneca plc | $295.54B | +140.97% |
| MRK | Merck & Co Inc | $291.57B | +137.73% |
| NVS | Novartis AG | $288.93B | +135.58% |
| NVO | Novo Nordisk | $224.93B | +83.39% |
| AMGN | AMGEN Inc | $193.39B | +57.68% |
| GILD | Gilead Sciences Inc | $163.57B | +33.37% |
| PFE | Pfizer Inc | $141.25B | +15.17% |
| SNY | Sanofi | $105.20B | -14.23% |
| GSK | GSK Plc | $104.78B | -14.57% |
| BIIB | Biogen Inc | $29.03B | -76.33% |
| GRFS | Grifols SA | $4.91B | -96.00% |
| OGN | Organon & Company | $3.54B | -97.11% |
| AMRN | Amarin Corp | $303.37M | -99.75% |
| SCLX | Scilex Holding Company | $78.29M | -99.94% |
| MIRA | Mira Pharmaceuticals Inc | $39.50M | -99.97% |
| NSRX | Nasus Pharma Ltd | $28.10M | -99.98% |
| MDCXW | Medicus Pharma Ltd warrant | $19.20M | -99.98% |
| MDCX | MDCorp | $13.93M | -99.99% |